Engrail Therapeutics
Janet has over 20 years of experience in the pharmaceutical/biotech industry with both large and small molecules. She has had various roles and responsibilities within clinical development. She was an integral member, author, and facilitator of several submissions for market authorization in multiple therapeutic areas at both GSK and Janssen. She is adept at strategic management and is results-driven with a breadth of expertise from Phase 1 (including first in humans), through Phase 4 studies. Janet has a clinical background in nursing, has an MBA, and is a Wharton, School of Business, graduate from the University of Pennsylvania.
This person is not in any offices
Engrail Therapeutics
Transforming the lives of patients with life-limiting diseases of the nervous system. Acquiring, developing and commercializing transformative medicines.